<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04926688</url>
  </required_header>
  <id_info>
    <org_study_id>20-6T/41</org_study_id>
    <nct_id>NCT04926688</nct_id>
  </id_info>
  <brief_title>High-risk Breast Lesions: A Multicenter Retrospective Study</brief_title>
  <official_title>Outcome of High-risk Breast Lesions Diagnosed on Image-guided Core Needle Biopsy: Results From a Multicenter Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ege University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ege University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this multicenter study, the goal was to document the excisional biopsy or follow-up&#xD;
      results of high risk lesions diagnosed on image guided CNB/VAB, and evaluate the clinical,&#xD;
      imaging and histologic features for associated malignancy risk. The possibility of upgrade&#xD;
      related to histologic subtype, tissue sampling and other variables was also evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective multicentric study that include 1345 patients from 30 centers.&#xD;
&#xD;
      Patients who had a diagnosis of high risk lesions (HRL) on image guided core biopsy&#xD;
      (tru-cut/vacuum biopsy) were reviewed in a 12 year period (between 2008 and 2020). The&#xD;
      lesions included were ADH, LN (ALH/LCIS), papilloma (without or with atypia), RS, and FEA.&#xD;
&#xD;
      The patients who managed with an excisional biopsy or having at least 1 year follow-up&#xD;
      documentation following the diagnosis of borderline lesion were included in the study.&#xD;
&#xD;
      Radiological findings, diameter of lesion (&gt;15 vs &lt;15 mm), needle biopsy type (14-16G vs&#xD;
      9-12G), sampling method and number of samplings (4 and &gt;4 vs &lt;4) were documented.&#xD;
&#xD;
      IBM SPSS Version 25.0 statistical package program was used for analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 10, 2020</start_date>
  <completion_date type="Actual">June 10, 2021</completion_date>
  <primary_completion_date type="Actual">January 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>upgrade rates related to histologic subtype, tissue sampling and other variables</measure>
    <time_frame>one year</time_frame>
    <description>the results from excisional biopsy or at least 1 year follow-up documentation</description>
  </primary_outcome>
  <enrollment type="Actual">1345</enrollment>
  <condition>Premalignant Lesion</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The women with diagnosis of atypical ductal hyperplasia, lobular neoplasia, flat epithelial&#xD;
        atypia, papilloma and radial scar on image guided core needle biopsy were studied&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        High risk lesions on image guided needle biopsy which includes ADH, LN, FEA, papilloma or&#xD;
        radial scar&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        High risk lesion of fibroepithelial tumors and mucocele like tumors&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aysenur Oktay, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ege University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ozge Aslan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ege University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ege University</name>
      <address>
        <city>Ä°zmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 10, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ege University</investigator_affiliation>
    <investigator_full_name>Aysenur Oktay</investigator_full_name>
    <investigator_title>Prof Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After finishing statistical analysis the results will be published</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>3 months</ipd_time_frame>
    <ipd_access_criteria>after publication</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

